Motolimod

DRUG3 trials

Sponsors

Celgene, Ludwig Institute for Cancer Research, Presage Biosciences

Conditions

HNSCCOvarian CancerSquamous Cell Carcinoma of the Head and Neck

Early Phase 1

Intratumoral Microdosing of Motolimod in HNSCC

TerminatedNCT04272333

Presage BiosciencesHNSCC

Start: 2021-10-15End: 2022-03-25Updated: 2022-04-14

Phase 1

A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab

TerminatedNCT02124850

CelgeneSquamous Cell Carcinoma of the Head and Neck

Start: 2014-10-28End: 2016-10-31Updated: 2019-10-25

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

CompletedNCT02431559

Ludwig Institute for Cancer ResearchOvarian Cancer

Start: 2015-12-02End: 2021-06-10Updated: 2022-10-10

Related Papers

A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC)

Annals of Oncology2018-10-0116 citations

A phase Ib study of neoadjuvant immune biomarker modulation with cetuximab and motolimod in head and neck cancer (HNC).

Journal of Clinical Oncology2015-05-20